Home > Oncology > ESMO 2021 > Genitourinary Cancer > Pembrolizumab has durable effect in previously treated MSI-H/dMMR advanced endometrial cancer

Pembrolizumab has durable effect in previously treated MSI-H/dMMR advanced endometrial cancer

Presented By
Prof. David O’Malley, Ohio State University, USA
Conference
ESMO 2021
Trial
Phase 2, KEYNOTE-158
Longer follow-up from the phase 2 KEYNOTE-158 trial showed pembrolizumab to have promising and long-standing efficacy in patients with previously treated MSI-H/dMMR advanced endometrial cancer. Treatment options for previously treated, advanced, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumours are limited. Pembrolizumab showed a durable and clinically meaningful benefit in previously treated, advanced MSI-H/dMMR tumours – including endometrial cancer – in the non-randomised, open-label, phase 2 KEYNOTE-158 study (NCT02628067) [1]. Prof. David O’Malley (Ohio State University, USA) presented longer follow-up data in 90 patients with previously treated, advanced, MSI-H/dMMR endometrial cancer [2]. Patients received pembrolizumab (200 mg every 3 weeks) for up to 35 cycles. Primary endpoint was overall response rate (ORR); seco...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on